Phase 2 N=7 18F-FSPG PET/CT for Cancer Patients on Therapy
B-Cell Neoplasm · Estrogen Receptor Negative · HER2/Neu Negative
Primary: Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment — -1.69; -0.64 g/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03 — 16; 18; 13; 11 Number of Events
Phase 2 N=5 An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
Sickle Cell Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events During Dosing of GBT440 for up to 6 Months. — 2; 1; 1 Participants
Phase 2 N=35 IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.
Foreign-Body Reaction · Inflammation · Effusion (L) Knee
Primary: Safety: Adverse Events — 0 participants
Phase 2 N=55 A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) on Day 8 — 17.83; 19.15; 19.59; 17.51 mm Hg
Phase 2 N=32 Gulf War Illness: Evaluation of an Innovative Detoxification Program
Gulf War Illness
Primary: Short Form-36 for Veterans Quality of Life Physical Component Summary Scores — 30.3; 36.7; 38.2; 35.7 score on a scale — p=<0.05
Phase 2 N=20 Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Metastatic Melanoma
Primary: Number and Frequency of Dose Limiting Toxicities (DLTs) With High-dose Calcitriol in Combination With Temozolomide — 0; 0; 0 DLT
Phase 2 N=10 Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Phase 2 N=109 Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Participants With Clinical Cure in Each Study Arm — 11; 8 Participants — p=0.420
Phase 2 N=271 Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects
Infections, Meningococcal
Primary: Meningococcal Serum Bactericidal Antibodies/Assay (rSBA) Titers — 6868.8; 13014.9; 1945.8; 5494.6 Titers
Phase 2 N=2 A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
Ovarian Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events — 2; 0 Participants
Phase 2 N=64 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Neuroblastoma · Rhabdomyosarcoma · Ewing's Sarcoma
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 0; 0; 0 Participants
Phase 2 N=178 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) as Determined by Investigator, Analyzed Using FDA Guidelines — 101; 66 days — p=0.113
Phase 2 N=23 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase — 4; 3; 3; 2 Participants
Phase 2 N=224 An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
Schizophrenia, Acute Episode
Primary: Least Squares Mean (LSM) Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -14.6; -17.2; -10.0 Score on a Scale — p=0.440